The "lively" cytokines network in β-Thalassemia Major-related osteoporosis

Bone

Volumn 40, Issue 6, 2007, Pages 1588-1594

  Morabito, Nunziata ^a   Russo, Giuseppina T ^a   Gaudio, Agostino ^a   Lasco, Antonino ^a   Catalano, Antonio ^a   Morini, Elisa ^a   Franchina, Fabio ^a   Maisano, Domenica ^a   La Rosa, Mariangela ^a   Plota, Maria ^a   Crifò, Adolfa ^a   Meo, Anna ^a   Frisina, Nicola ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Bone turnover; Cytokine; Osteoporosis; RANKL; Thalassemia Major

Indexed keywords

CYTOKINE; DEOXYPYRIDINOLINE; ERYTHROPOIETIN; ESTRADIOL; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BETA THALASSEMIA; BODY MASS; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FEMUR NECK; HUMAN; LUMBAR VERTEBRA; MALE; OSTEOPOROSIS; THALASSEMIA MAJOR;

ADULT; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOKINES; FEMALE; HUMANS; MALE; OSTEOPOROSIS;

EID: 34248634860     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.02.020     Document Type: Article

References (57)

1. Ruggiero L., and De Sanctis V. Multicentre study on prevalence of fractures in transfusion-dependent thalassaemic patients. J. Pediatr. Endocrinol. Metab. 11 (1998) 773-778
2. Jensen C.E., Tuck S.M., Agnew J.E., Koneru S., Morris R., Yardumian A., et al. High prevalence of low bone mass in thalassaemia major. Br. J. Haematol. 103 (1998) 911-915
3. Voskaridou E., Kyrtsonis M.C., Terpos E., Skordili M., Theodoropoulos I., Bergele A., et al. Bone resorption is increased in young adults with thalassaemia major. Br. J. Haematol. 112 (2001) 36-41
4. Soliman A.T., El Banna N., Abdel Fattah M., El Zalabani M.M., and Ansari B.M. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. Metabolism 47 (1998) 541-548
5. Lasco A., Morabito N., Gaudio A., Crisafulli A., Meo A., Denuzzo G., et al. Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis. Endocrinol. Invest. 25 (2002) 338-344
6. Mahachoklertwattana P., Sirikulchayanonta V., Chuansumrit A., Karnsombat P., Choubtum L., Sriphrapradang A., et al. Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J. Clin. Endocrinol. Metabol. 88 (2003) 3966-3972
7. Jensen C.E., Tuck S.M., Old J., Morris R.W., Yardumian A., De Sanctis V., et al. Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia. Eur. J. Haematol. 59 (1997) 76-81
8. Wonke B., Jensen C., Hanslip J.J., Prescott E., Lalloz M., Layton M., et al. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J. Pediatr. Endocrinol. Metab. 11 (1998) 795-801
9. Moulas A., Challa A., Chaliasos N., and Lapatsanis P.D. Vitamin D metabolites (25-hydroxyvitamin D, 24,25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D) and osteocalcin in beta-thalassaemia. Acta Paediatr. 86 (1997) 594-599
10. De Sanctis V., Pinamonti A., Di Palma A., Sprocati M., Atti G., Gamberini M.R., et al. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur. J. Pediatr. 155 (1996) 368-372
11. Chan Y.L., Pang L.M., Chik K.W., Cheng J.C., and Li C.K. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr. Radiol. 32 (2002) 492-497
12. Anapliotou M.L., Kastanias I.T., Psara P., Evangelou E.A., Liparaki M., and Dimitriou P. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin. Endocrinol. 42 (1995) 279-287
13. Raiola G., Galati M.C., De Sanctis V., Nicoletti C.M., Pintor C., De Simone M., et al. Growth and puberty in thalassemia major. J. Pediatr. Endocrinol. Metab. 2 (2003) 259-266
14. Mahachoklertwattana P., Chuansumrit A., Sirisriro R., Choubtum L., Sriphrapradang A., and Rajatanavin R. Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with beta-thalassaemia disease. Clin. Endocrinol. 58 (2003) 273-279
15. Vichinsky E.P. The morbidity of bone disease in thalassemia. Ann. N.Y. Acad. Sci. 850 (1998) 344-348
16. De Sanctis V., Stea S., Savarino L., Scialpi V., Traina G.C., Chiarelli G.M., et al. Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine. J. Pediatr. Endocrinol. Metabol. 11 (1998) 827-833
17. Carmina E., Di Fede G., Napoli N., Renda G., Vitale G., Lo Pinto C., et al. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif. Tissue Int. 74 (2004) 68-71
18. Dresner Pollack R., Rachmilewitz E., Blumenfeld A., Idelson M., and Goldfarb A.W. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br. J. Haematol. 111 (2000) 902-907
19. Voskaridou E., Terpos E., Spina G., Palermos J., Rahemtulla A., Loutradi A., et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br. J. Haematol. 123 (2003) 730-737
20. Morabito N., Gaudio A., Lasco A., Atteritano M., Pizzoleo M.A., Cincotta M., et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia induced osteoporosis: new pieces of the puzzle. J. Bone Miner. Res. 19 (2004) 722-727
21. Lasco A., Morabito N., Gaudio A., Buemi M., Wasniewska M., and Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos. Int. 12 (2001) 570-575
22. Chambers T.J. Regulation of the differentiation and function of osteoclasts. J. Pathol. 192 (2000) 4-13
23. Teitelbaum S.L. Bone resorption by osteoclasts. Science 289 (2000) 1504-1508
24. Kwan Tat S., Padrines M., Theoleyre S., Heymann D., and Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 15 (2004) 49-60
25. Pfeilschifter J., Köditz R., Pfohl M., and Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 23 (2002) 90-119
26. Manolagas S.C., and Jilka R.L. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332 (1995) 305-311
27. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. 11 (1996) 1043-1051
28. Jilka R.L. Cytokines, bone remodelling, and estrogen deficiency: a 1998 update. Bone 23 (1998) 75-81
29. Spelsberg T.C., Subramaniam M., Riggs B.L., and Khosla S. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol. Endocrinol. 13 (1999) 819-828
30. Pacifici R., Rifas L., Teitelbaum S., Slatopolsky E., McCracken R., Bergfeld M., et al. Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc. Natl. Acad. Sci. 84 (1987) 4616-4620
31. Bismar H., Diel I., Ziegler R., and Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J. Clin. Endocrinol. Metab. 80 (1995) 3351-3355
32. Cheleuitte D., Mizuno S., and Glowacki J. In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J. Clin. Endocrinol. Metab. 83 (1998) 2043-2051
33. Passeri G., Girasole G., Jilka R.L., and Manolagas S.C. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology 133 (1993) 822-828
34. Hyams J.S., Wyzga N., Kreutzer D.L., Justinich C.J., and Gronowicz G.A. Alterations in bone metabolism in children with inflammatory bowel disease: an invitro study. J. Pediatr. Gastroenterol. Nutr. 24 (1997) 289-295
35. Issenman R.M. Bones in Crohn's: cytokines, a missing link?. J. Pediatr. Gastroenterol. Nutr. 24 (1997) 361-362
36. Gradaigh O.'., Ireland D., Bord S., and Compston J.E. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann. Rheum. Dis. 63 (2004) 354-359
37. Kotake S., Sato K., Kim K.J., Takahashi N., Udagawa N., and Nakamura I. Interleukin-6 and soluble interleukin-6 receptors found in synovial fluids are responsible for inducing joint disruption in patients with rheumatoid arthritis. J. Bone Miner. Res. 9 (1994) S140
38. Working Party of the General Haematology Task Force of the British Committee for Standards in Haematology. The laboratory diagnosis of haemoglobinopathies. Br. J. Haematol. 101 (1998) 783-792
39. Aggeli C., Antoniades C., Cosma C., Chrysohoou C., Tousoulis D., Ladis V., et al. Endothelial dysfunction and inflammatory process in transfusion-dependent patients with beta-thalassemia major. Int. J. Cardiol. 105 (2005) 80-84
40. Butthep P., Rummavas S., Wisedpanichkij R., Jindadamrongwech S., Fucharoen S., and Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am. J. Hematol. 70 (2002) 100-106
41. Salsaa B., and Zoumbos N.C. A distinct pattern of cytokine production from blood mononuclear cells in multitransfused patients with beta-thalassaemia. Clin. Exp. Immunol. 107 (1997) 589-592
42. Gowen M., Wood D.D., Ihrie E.J., McGuire M.K.B., and Russell R.G.G. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306 (1983) 378-380
43. Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis-the second decade. Endocrinology 139 (1998) 2659-2661
44. Rogers A., and Eastell R. Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood. J. Bone Miner. Res. 130 (1998) 1577-1586
45. Lee S.K., Gardner A.E., Kalinowski J.F., Jastrzebski S.L., and Lorenzo J.A. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone 38 (2006) 678-685
46. Jimi E., Nakamura I., Ikebe T., Akiyama S., Takahashi N., and Suda T. Activation of NF-kB is involved in the survival of osteoclast promoted by interleukin-1. J. Biol. Chem. 273 (1998) 8799-8805
47. Rifas L., Kenney J.S., Marcelli M., Pacifici R., Dawson L.L., Cheng S., et al. Production of interleukin-6 in human osteoblasts and human bone marrow stromal cells: evidence that induction by interleukin-1 and tumor necrosis factor- is not regulated by ovarian steroids. Endocrinology 136 (1995) 4056-4067
48. Elias J.A., and Lentz V. IL-1 and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA. J. Immunol. 145 (1990) 161-166
49. Klein B., Wijdenes J., Zhang X.-G., Jourdan M., Boiron J.M., Brochier J., et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78 (1991) 1198-1204
50. Roodman G.D., Kurihara N., Ohsaki Y., Kukita A., Hosking D., Demulder A., et al. Interleukin 6: a potential autocrine/paracrine factor in Paget's disease of bone. J. Clin. Invest. 89 (1992) 46-52
51. Nanes M.S. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321 (2003) 1-15
52. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., and Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106 (2000) 1481-1488
53. Lange U., Teichmann J., Muller-Ladner U., and Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatology 44 (2005) 1546-1548
54. Saidenberg-Kermanac'h N., Corrado A., Lemeiter D., deVernejoul M.C., Boissier M.C., and Cohen-Solal M.E. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35 (2004) 1200-1207
55. Miheller P., Muzes G., Zagoni T., Toth M., Racz K., and Tulassay Z. Improvement of bone metabolism after infliximab therapy in Crohn's disease. Orv. Hetil. 146 (2005) 1477-1480
56. Horowitz M.C. Cytokines and estrogen in bone: antiosteoporotic effects. Science 260 (1993) 626-627
57. Gurevitch O., and Slavin S. The haematological etiology of osteoporosis. Med. Hypotheses 67 (2006) 729-735